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Abstract
Background: Hepatitis C virus (HCV) elimination is being seriously considered globally. Current elimination models
require a combination of highly effective HCV treatment and harm reduction, but high treatment costs make such
strategies prohibitively expensive. Vaccines should play a key role in elimination but their best use alongside
treatments is unclear. For three vaccines with different efficacies we used a mathematical model to estimate the
additional reduction in HCV prevalence when vaccinating after treatment; and to identify in which settings vaccines
could most effectively reduce the number of treatments required to achieve fixed reductions in HCV prevalence
among people who inject drugs (PWID).
Methods: A deterministic model of HCV transmission among PWID was calibrated for settings with 25, 50 and
75 % chronic HCV prevalence among PWID, stratified by high-risk or low-risk PWID. For vaccines with 30, 60 or 90 %
efficacies, different rates of treatment and vaccination were introduced. We compared prevalence reductions achieved
by vaccinating after treatment to prevent reinfection and vaccinating independently of treatment history in the
community; and by allocating treatments and vaccinations to specific risk groups and proportionally across risk groups.
Results: Vaccinating after treatment was minimally different to vaccinating independently of treatment history, and
allocating treatments and vaccinations to specific risk groups was minimally different to allocating them proportionally
across risk groups. Vaccines with 30 or 60 % efficacy provided greater additional prevalence reduction per vaccination
in a setting with 75 % chronic HCV prevalence among PWID than a 90 % efficacious vaccine in settings with 25 or 50 %
chronic HCV prevalence among PWID.
Conclusions: Vaccinating after treatment is an effective and practical method of administration. In settings with high
chronic HCV prevalence among PWID, even modest coverage with a low-efficacy vaccine could provide significant
additional prevalence reduction beyond treatment alone, and would likely reduce the cost of achieving prevalence
reduction targets.
Background
Hepatitis C virus (HCV) elimination is now being
seriously considered globally [1–3]. In developed coun-
tries, people who inject drugs (PWID) are at greatest risk
of HCV infection [4–6]. The prevalence of HCV RNA
among PWID varies globally, ranging from 10 to 97 %
[6, 7] and is estimated to be greater than 50 % in many
countries. For this reason elimination models have fo-
cused on this group, using a combination of treatment
as prevention and harm reduction, including opioid sub-
stitution therapy (OST) and needle and syringe pro-
grammes (NSPs) [8, 9]. The advent of highly effective
direct-acting antiviral (DAA) treatment, with 90 % cure
rates, improved tolerability and a comparably short dur-
ation of therapy (up to 12 weeks) [10–12] has increased
optimism about achieving elimination. A number of
fixed-dose combinations such as sofosbuvir and ledipas-
vir [10–13], and paritaprevir/ritonavir/ombitasvir and
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dasabuvir [14], have been licenced by the US Food and
Drug Administration and other countries’ regulatory
bodies, with a number of other drug combinations in
phase 3 clinical trials. At the same time, there is real
concern that the high cost of DAAs and large numbers
of people requiring treatment make current elimination
strategies prohibitively expensive, reducing the likeli-
hood of substantial progress in HCV prevalence reduc-
tion in the next 15 years.
Vaccines typically represent the most cost-effective
strategy to prevent infectious disease and development is
continuing [15]. HCV is a challenge for vaccine develop-
ment owing to its high sequence variation, resulting in
the need for a vaccine to provide broad protection
against the seven genotypes and >50 subtypes circulating
worldwide. Several prophylactic vaccines are in clinical
and preclinical development, the most advanced of
which is the T cell-based approach. This employs a
chimpanzee adenovirus prime followed by a modified
vaccinia Ankara virus boost strategy encoding the NS3,
NS4, NS5A and NS5B proteins of genotype 1b, which
generate long-lived, broad T cell responses. It is now in
phase 1/2 clinical trials to determine efficacy in prevent-
ing chronic HCV [15]. Alternative vaccine strategies use
the viral glycoproteins to generate neutralizing antibody
responses. These include a gpE1/E2 vaccine [16, 17]
tested in a phase 1 clinical trial in humans and demon-
strating some cross-neutralization capacity, and others
in preclinical development [18–21]. However, the avail-
ability of highly effective HCV treatments has raised
questions as to what benefits a HCV vaccine may pro-
vide, particularly if it were not 100 % effective as current
research suggests [22, 23].
HCV vaccines are likely to play an important role in
HCV elimination but it is unclear how best to use them
alongside highly effective, but costly, HCV treatments.
With this in mind, we explored the possible benefit of
three different HCV vaccines in different epidemic set-
tings when introduced at the same time as scaled-up
treatment. Administering a vaccination after treatment
could be a useful strategy for limiting reinfection and is
practical because the HCV RNA status of the patients is
already known. In addition, it could be an effective way
of targeting higher-risk individuals because they are
more likely to be infected.
In this study we consider settings with low (25 %),
medium (50 %) or high (75 %) HCV RNA prevalence
among PWID. Distinguishing the presence of HCV RNA
(current HCV infection) from HCV antibodies in indi-
viduals, which could be present owing to either acute,
chronic or resolved infection, requires a polymerase
chain reaction test that is rarely performed in epidemio-
logical studies. Countries with low HCV antibody preva-
lence among PWID include Czech Republic (25 %),
Tanzania (22 %) and Uruguay (22 %); countries with
medium HCV antibody prevalence among PWID in-
clude Argentina (54 %), Australia (55 %), Iran (50 %),
the UK (51 %) and Uzbekistan (52 %); and countries
with high HCV antibody prevalence among PWID in-
clude France (74 %), Indonesia (77 %), the USA (73 %)
and Vietnam (74 %) [6]. However, the prevalence of
HCV antibodies may be up to 25 % higher than the
prevalence of HCV RNA [24]. In each of the three HCV
RNA prevalence settings, we considered three different
vaccines, which had low (30 %), medium (60 %) and high
(90 %) efficacies. In each scenario, a deterministic model
of HCV transmission among PWID was used to predict
(1) the additional prevalence reduction that could be
achieved by vaccinating after treatment and whether this
would be as effective as a community-based vaccination
programme; (2) how much additional efficiency could be
gained by targeting both vaccinations and treatments at
either high or low injecting risk PWID; and (3) under
what circumstances a scaled-up vaccine programme
could most effectively reduce the number of treatments
required to achieve fixed prevalence reduction targets.
Methods
Model description
We used a modified version of the open deterministic
compartment model of HCV transmission among PWID
from Martin et al. [25] shown in Fig. 1, assuming a
prophylactic vaccine with efficacy ε was available that of-
fered a duration of immunity greater than the length of
injecting career and perfect protection for a proportion ε
of PWID vaccinated, and no protection for the remaining
(1−ε) who ‘fail vaccination’.
PWID were distinguished as either susceptible and
not vaccinated (S, HCV RNA- population, including
infection-naïve PWID or PWID achieving a sustained
viral response [SVR] either spontaneously or through
treatment); chronically infected and not vaccinated
(C, PWID who do not spontaneously clear their infec-
tion, including both initial infections and reinfections); in
treatment and not vaccinated (T); vaccinated and im-
mune (V); susceptible after failing vaccination (Ŝ); chron-
ically infected after failing vaccination (Ĉ); in treatment
after failing vaccination (T^ ); or chronically infected after
failing treatment (F). Each compartment was stratified by
injecting risk (high versus low, i = 1 or 0 respectively,
with risk definition based on the proportion of PWID ex-
periencing unstable housing—see Table 1; populations
mixed proportionally), with the infectivity of high-risk
PWID increased by a factor Γ. PWID at high risk
remained there for an average duration (1/κ), and the
total size of the high-risk population was held fixed
and calibrated by varying the recruitment parameter η.
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Estimates for Γ, κ and the size of the high-risk popula-
tion can be found in Table 1.
PWID leave each compartment owing to cessation of
injecting or death at a fixed rate μ and the total popula-
tion is held constant by entry of new PWID who are as-
sumed to be unvaccinated and susceptible, with a fixed
proportion being high risk. Both vaccine-naïve suscep-
tible PWID and those who failed vaccination become in-
fected at a rate proportional to an infection rate π, the
risk-weighted number of susceptible PWID (with risk
weighting Γ for PWID at high risk), and the risk-
weighted proportion Ψ of PWID either currently in-
fected or in treatment and not achieving SVR. A propor-
tion (1−δ) of newly infected PWID fail to spontaneously
clear the virus and become chronically infected. A fixed
annual number Φ of treatment-naïve or reinfected
PWID (C and Ĉ) are recruited into treatment (or all
of them if C + Ĉ <Φ) selected proportionally from
unvaccinated and failed vaccination chronically infected
compartments (Ci and Ĉi) and across risk levels (i = 0, 1).
Treatment is completed after an average duration 1/ω
years, and the proportion (1−α) not achieving SVR
move to the failed treatment compartment where
they remain and are not retreated. Given the current
limited data on retreatment outcomes following treat-
ment failure with DAAs, the low numbers this is
likely to represent, and current limits on treatment
numbers, we believe this is the most practical way to
manage this group in the model. The proportion α
achieving SVR are either vaccinated (of which ε be-
comes immune and [1−ε] fail vaccination and move
to Ŝ) or returned to their respective susceptible
pools. A fixed annual number VT of vaccine-naïve
susceptible PWID (or all of S if S < VT) are vacci-
nated each year. Both injecting risk states are equally
eligible for vaccination.
The model was run to equilibrium without any
treatments or vaccinations and the initial conditions
Fig. 1 Model schematic
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(if non-zero) do not affect the steady-state values;
equilibrium prevalence and the proportion at high risk
were calibrated by varying the infection rate π and high-
risk recruitment rate η respectively to achieve the desired
scenario-dependent baseline conditions. After steady-state
with no treatments or vaccinations was reached,
(maximum) treatment and vaccination numbers were
introduced simultaneously. Model parameters were taken
from previously published studies [10–12, 24, 26–32],
with treatment parameters updated to reflect the lat-
est trial data on DAAs. These are provided with ref-
erences in Table 1.
Natural immunity following spontaneous clearance of
the virus was not included in the model, because al-
though this has been observed in humans [33, 34] and
chimpanzees [35], the percentage of patients likely to ex-
perience immunity, and for how long, is currently un-
clear. Previous modelling studies testing this feature
found minimal effects on model outcomes [36]; in par-
ticular, omission of this feature will lead to slightly lower
estimates for the infection parameter π used to calibrate
prevalence, and conservative estimates for the benefits
of vaccines in preventing transmission. Similarly, im-
munity following SVR was not included in the model.
Although the extent to which it occurs following treat-
ment with DAAs is currently unclear, we have assumed
it is similar to that following previous HCV treatments.
This is again a conservative assumption and means that
estimates of prevalence reduction due to treatment may
be understated.
Vaccination after treatment versus community-based
vaccination
To determine the additional prevalence reduction a vac-
cine could provide if administered as part of a treatment
regimen, for all combinations of vaccine efficacies of 30,
60 and 90 %; initial chronic HCV prevalence among
PWID of 25, 50 and 75 %; and treatment numbers of 10,
20 and 40/1,000 PWID per year (treated independent of
risk), the 15-year relative prevalence reduction was calcu-
lated and compared for (1) no vaccination; (2) vaccinating
all who were treated and had a SVR; (3) vaccinating
susceptible PWID (in equal numbers to successful
treatments, i.e. 90 % of those treated, independent of
risk); and (4) vaccinating all susceptible PWID and
all who were treated and had a SVR. The fourth cat-
egory would be unrealistic in practice but provides
an upper bound for the maximum relative prevalence
reduction that could be achieved.
Maximizing efficiency by treating and vaccinating specific
risk groups
For all combinations of vaccine efficacies of 30, 60 and
90 %; initial chronic HCV prevalence among PWID of
25, 50 and 75 %; treatment numbers of 10, 20 and 40/
1,000 PWID per year; and vaccination numbers of 10, 20
and 40/1,000 susceptible PWID per year, each scenario
was run multiple times as the proportion of treatments
and the proportion of vaccination courses administered
to high-risk PWID took the values 0, 0.2, 0.4, 0.6, 0.8
and 1. Relative prevalence reduction was measured after
Table 1 Model parameters and references
Parameter Symbol Value References
Duration of injecting career 1/μ1 14 years Fazito et al. global average [26]
Mortality rate μ2 0.0083 per year Stoové et al. [27]
Exit rate μ μ1 + μ2 per year
Proportion at high risk, defined as the proportion
of PWID experiencing unstable housing [16]
Vary η to calibrate 0.17 O’Keefe et al. [28]
Duration at high risk 12/κ 13 months O’Keefe et al. [28]
Recruitment to high risk η Calibrated to proportion at high risk
Infection risk factor of high-risk PWID compared
to low-risk PWID
Γ 3.6 Turner et al. [29], Allen et al. [30],
Aitken et al. [31]
Infection rate π Calibrated to initial prevalence
Proportion of infected who spontaneously clear δ 0.26 Micallef et al. [24]
Proportion treated who are cured (interferon-free
DAAs, all genotypes)
α 0.9 Lawitz et al. [10], Gane et al. [11],
Poordad et al. [12]
Treatment duration (interferon-free DAAs,
all genotypes)
52/ω 12 weeks Lawitz et al. [10], Gane et al. [11],
Poordad et al. [12], Chen et al. [32]
Vaccine efficacy ε 30 %, 60 %, 90 % Assumed
Vaccine duration of protection Greater than the length of injecting
career
Assumed
DAA direct-acting antiviral, PWID people who inject drugs
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15 years for each run and the ‘most efficient’ and ‘least
efficient’ methods for allocating treatments and vaccina-
tions were defined as the ones achieving the maximum
and minimum, respectively, relative prevalence reduction.
Relative prevalence reduction after 15 years using the
most efficient method was compared to selecting pro-
portionally across risk groups both chronically infected
PWID for treatment and susceptible PWID for vaccin-
ation for all combinations of vaccine efficacies, initial
prevalence, treatment numbers and vaccination numbers.
This represents the maximum theoretical benefit in preva-
lence reduction obtained by allocating treatments and vac-
cinations most efficiently to injecting risk groups.
Reaching fixed prevalence reduction targets: simultaneously
introducing a vaccination programme to reduce treatment
numbers
Treatment rates of between 0 and 80/1,000 PWID per
year and simultaneous vaccinations rates of between 0
and 200/1,000 susceptible PWID per year were simu-
lated, with both treatments and vaccinations allocated
proportionally across risk groups. Each simulation was
rerun for vaccine efficacies of 30, 60 and 90 % and initial
chronic prevalence of 25, 50 and 75 %, and relative
prevalence reduction was measured every five years for a
30-year period. Linear regression was used to estimate
the relationship between vaccination numbers and treat-
ment numbers required to achieve 25, 50 and 75 % rela-
tive prevalence reductions after 10, 15 and 30 years for
each scenario. These estimates can be interpreted as
measuring the effectiveness of a vaccine at reducing the
number of treatments required to maintain prevalence
reduction targets.
The basic reproduction number
The basic reproduction number (R0)—the average num-
ber of new infections caused by one typical infected indi-
vidual in a completely susceptible population—is an
extremely important value for infectious diseases. Values
of R0 < 1 indicate that the disease-free state is asymptot-
ically stable, and so the disease is expected to eventually
become extinct, while values of R0 > 1 indicate that the
disease-free state is asymptotically unstable and the dis-
ease is able to invade a population [37]. Hence, the exist-
ence of equilibrium prevalence in our model at baseline
(with no imported infections) indicates that R0 > 1. In-
terventions that are able to reduce R0 from above one to
below one will have the most significant impacts—for
our model this can be done with a vaccine to reduce the
number of susceptible individuals in the population (i.e.
increasing the ‘herd immunity’ to a point where HCV
can no longer persist).
For settings with 25, 50 and 75 % initial chronic HCV
prevalence among PWID (and hence different values for
the calibrated transmission parameter π), R0 was calcu-
lated [38, 39], and in each case the proportion of suscep-
tible PWID that would need to be vaccinated to reduce
R0 from above one to below one was determined.
Details of these calculations are provided in Additional
file 1: Supplementary material.
Sensitivity of parameters
In separate scenarios, the infectivity of the high-risk
population was doubled from 3.6 to 7.2, the proportion
of PWID at high risk was doubled from 0.17 to 0.34, the
duration of injecting career was halved from 14 years to
7 years, the average length of time at high risk was in-
creased to 14 years (the length of injecting career), and
fully assortative mixing amongst injecting risk groups
(e.g. high-risk PWID only infect/are infected by high-
risk PWID) was assumed. A scenario where the vaccine
efficacy was halved if administered after treatment was
also explored as follows. For scenarios where only
susceptible PWID were vaccinated (i.e. not as part of
treatment), the overall vaccine efficacy was modified ac-
cording to movements into the susceptible compart-
ment, namely:
ε tð Þ ¼ ε^  μ N0 þ N1ð Þ þ
1
2ωα T 0 þ T 1ð Þ
μ N0 þ N1ð Þ þ ωα T0 þ T 1ð Þ ;
where ε^ is the stated efficacy. Here, we have implicitly
used time-dependent movements to approximate the
composition of the susceptible compartment as either
previously treated or treatment-naïve. Under each of the
alternate parameter assumptions, the analyses compar-
ing vaccination after treatment to vaccination in the
community and maximizing efficiency by treating and
vaccinating specific risk groups were repeated.
Results
Vaccination after treatment versus community-based
vaccination
The 15-year relative prevalence reduction when 20/1,000
PWID were treated each year was compared in settings
with 25, 50 and 75 % initial chronic HCV prevalence
when (1) everyone was vaccinated after successful treat-
ment; (2) 18/1,000 PWID were vaccinated in the com-
munity each year; and (3) everyone not chronically
infected and not previously vaccinated was vaccinated
each year with different efficacy vaccines (30, 60 and
90 %) (Fig. 2). Vaccinating after treatment was as effect-
ive at reducing prevalence as vaccinating an equivalent
number of PWID in the community. This remained true
for other treatment numbers considered (see Additional
file 1: Figure S1). A vaccine provided greater benefit in a
setting with high chronic HCV prevalence among
PWID; in a setting with low chronic HCV prevalence
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among PWID, modest treatment numbers were suffi-
cient to virtually eliminate the epidemic.
Improving efficiency by treating and vaccinating specific
risk groups
For settings with low or medium chronic HCV preva-
lence among PWID, the most efficient method was to
treat and vaccinate high-risk PWID. For a setting with
high chronic HCV prevalence among PWID, the most
efficient method was to treat low-risk PWID and vaccin-
ate high-risk PWID. The difference in a setting with high
chronic HCV prevalence among PWID can be attributed
to pre-emptive saturation [40] of HCV infection among
high-risk PWID; enough contacts are ‘wasted’ on already
infected PWID that it becomes more beneficial to treat
low-risk PWID.
For a vaccine efficacy of 90 % and treatment or vaccin-
ation numbers of 10, 20 and 40/1,000 PWID per year,
allocating treatments and vaccinations most efficiently in
the model provided little additional benefit to 15-year
relative prevalence reduction than proportional alloca-
tion (Fig. 3). These additional benefits were even smaller
for lower vaccine efficacies.
Reaching fixed prevalence reduction targets:
simultaneously introducing a community vaccination
programme to reduce treatment numbers
The relationship between vaccination and treatment
numbers that would achieve a 50 % relative prevalence
reduction is approximately linear until allowed vaccin-
ation numbers become sufficient to cover the entire sus-
ceptible population (Fig. 4). For example, in a scenario
with 50 % initial chronic prevalence, this is approxi-
mately 110 or 90/1,000 PWID each year for the 10 or
15 year models respectively. Allowing vaccination num-
bers beyond this only marginally alleviates the required
treatment numbers—smaller additional benefits are the
result of complete vaccination coverage being achieved
sooner. Figure 4 also shows that in a setting with 50 %
initial chronic HCV prevalence among PWID, a 90 % ef-
ficacious vaccine could achieve a 50 % relative preva-
lence reduction without any treatments by vaccinating
approximately 90/1,000 PWID each year for 15 years.
For various scenarios, the annual numbers of suscep-
tible vaccinations needed per unit of treatment withheld
to maintain a specified reduction in prevalence (where
vaccination numbers are insufficient to achieve complete
coverage) are listed in Table 2. For example, in a setting
with 50 % initial chronic HCV prevalence among PWID
and a vaccine that was 60 % efficacious, instead of using
treatment alone to achieve a 50 % relative prevalence re-
duction, substituting one annual treatment course for
approximately five (4.8, see Table 2) annual susceptible
vaccinations would result in the same relative prevalence
reduction after 15 years, and greater reductions into the
future.
Vaccinations become more effective at alleviating re-
quired treatment numbers when longer-term targets are
used (see Additional file 1: Figure S2, left panel), and in
settings where prevalence, and hence reinfection inci-
dence [41], is high (see also Additional file 1: Figure S3).
Vaccinations are slightly more effective at alleviating re-
quired treatment numbers for lower prevalence reduc-
tion targets, provided treatment numbers are insufficient
Fig. 2 Vaccination strategy: comparison of relative prevalence reduction using fixed treatment numbers of 20/1,000 PWID per year and vaccinating all
who were treated and had a SVR (A); vaccinating an equivalent number independently of treatment history in the community (B); and vaccinating
everyone not infected (C). Settings with 75, 50 and 25 % initial chronic HCV prevalence among PWID, vaccines with 30, 60 and 90 % efficacies.
HCV hepatitis C virus, PWID people who inject drugs
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to treat all infected PWID within the time frame (see
Additional file 1: Figure S2, right panel).
For example, Melbourne, Australia is a setting with
approximately 50 % chronic HCV prevalence among an
estimated 25,000 PWID [42], and the proportion of
PWID at high-risk, the average duration at high-risk,
and length of injecting career parameters are suitable for
this setting [25]. Figure 4 shows that to achieve a 50 %
relative prevalence reduction after 15 years would re-
quire 26/1,000 PWID be treated each year, however if a
60 % efficacious vaccine were available, the same preva-
lence reduction target could be achieved with 22 treat-
ments and 20 vaccinations per 1,000 PWID each year
(i.e. Table 2 shows that approximately five vaccinations
are required for every treatment reduction)—a reduction
of approximately 100 treatment courses per year. Simi-
larly, the model predicts that a 25 % relative prevalence
reduction could be achieved by either treating 15/1,000
PWID each year, or treating 12/1,000 and vaccinating
12/1,000 PWID each year. After calibrating for an
Fig. 3 Risk allocation: comparison of relative prevalence reduction after 15 years using a proportional versus a most efficient injecting risk
targeted treatment and vaccination strategy. PWID people who inject drugs
Fig. 4 Achieving fixed targets: combinations of annual treatments and susceptible vaccinations that achieve a 50 % relative prevalence reduction
target after 10 years (grey) and 15 years (black) with various vaccine efficacies (30, 60 and 90 %) for a 50 % initial chronic HCV prevalence among
PWID. HCV hepatitis C virus, PWID people who inject drugs
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equivalent prevalence reduction with either treatment
alone or treatment plus vaccination at 15 years, the
treatment plus vaccination combination became more
beneficial as time of follow-up increased. After 30 years,
it leads to a substantially greater prevalence reduction.
The basic reproduction number
For settings with 25, 50 and 75 % chronic HCV preva-
lence among PWID, the model estimated that the R0
values were 1.33, 2.08 and 4.33 respectively. In order to
reduce R0 from above one to below one, it would be ne-
cessary to successfully vaccinate 24, 52 and 77 % of the
susceptible population respectively, assuming PWID
were vaccinated independently of risk (similar to the re-
sults in Fig. 3, individuals cycling through periods of
high and low risk throughout their injecting career
means that targeting vaccinations to specific risk groups
has little effect on the required coverage). Achieving
these levels of successful coverage would be difficult or
impossible. For example, with a 60 % efficacious vaccine,
the maximum successful coverage is 60 % (when all sus-
ceptible PWID are vaccinated), and so for the above
example of Melbourne, coverage of 87 % would be re-
quired to reduce R0 to below one. Given the infrequent
interaction of PWID with healthcare services, vaccinating
high proportions of this population is likely to be difficult
in practice. This indicates that further interventions, such
as up-scaling NSPs, would be required to decrease the
transmissibility of HCV so that R0 is less than one.
Sensitivity of parameters
In a setting with 50 % chronic HCV prevalence among
PWID, treating 20/1,000 PWID per year, and using a
vaccine with 90 % efficacy, halving the vaccine efficacy
after treatment (see ‘Methods’) led to vaccinating in the
community having 12 % more total impact after 15 years
than vaccinating after treatment (46 % versus 41 % rela-
tive prevalence reduction). Halving the length of inject-
ing career from 14 years to 7 years led to vaccinating in
the community having an additional 2.7 % impact after
15 years than vaccinating after treatment (38 % versus
37 % relative prevalence reduction). Increasing the dur-
ation spent at high risk from 13 months to 14 years led
to vaccinating after treatment having 1.4 % more impact
after 15 years than vaccinating in the community (73 %
versus 72 % relative prevalence reduction). Otherwise,
doubling the infectivity of the high-risk population from
3.6 to 7.2, doubling the proportion of PWID at high
risk from 0.17 to 0.34, and assuming fully assortative
mixing resulted in less than 1 % difference in 15-year
relative prevalence reduction between vaccination strat-
egies (Fig. 5).
The additional benefit of treating risk groups effi-
ciently was sensitive to the average duration at high risk.
In a setting with 50 % chronic HCV prevalence among
PWID, treating 20/1,000 PWID per year, and vaccinating
after treatment with a 60 % efficacious vaccine, an im-
provement in 15-year prevalence reduction of 6 % could
be achieved by allocating treatments to high-risk PWID
rather than proportionally across risk groups; however,
when the average duration at high risk was increased
from 13 months to 14 years, this increased to 19 % add-
itional impact (Fig. 6). As other parameters varied, the
possible improvement in 15-year prevalence reduction
changed to 11 % if the length of injecting career was
halved from 14 to 7 years; 11 % if the infectivity of the
Table 2 Achieving fixed targets: the annual number of susceptible PWID who must be vaccinated for every reduction in treatments
administered in order to maintain a specified reduction in prevalence
75 % relative prevalence
reduction target
50 % relative prevalence
reduction target
25 % relative prevalence
reduction target
Time to target (years) 10 15 30 10 15 30 10 15 30
25 % initial chronic HCV prevalence among PWID
Vaccine efficacy 90 % 17.7 13.9 8.5 14.1 10.4 6.7 11.2 8.0 5.6
60 % 26.8 21.3 14.1 21.2 15.5 10.0 17.0 12.1 8.5
30 % 60.9 41.6 38.1 41.9 30.8 20.0 34.9 24.6 16.9
50 % initial chronic HCV prevalence among PWID
90 % 5.8 4.3 2.9 4.3 3.2 2.1 3.4 2.4 1.6
60 % 8.6 6.3 4.3 6.5 4.8 3.2 5.1 3.7 2.4
30 % 17.2 13.0 8.9 13.0 9.7 6.5 10.3 7.5 4.9
75 % initial chronic HCV prevalence among PWID
90 % 2.0 1.4 1.0 1.4 1.0 0.7 1.1 0.8 0.5
60 % 3.0 2.1 1.5 2.2 1.5 1.0 1.6 1.1 0.8
30 % 5.6 4.3 2.9 4.3 3.1 2.1 3.2 2.3 1.5
HCV hepatitis C virus, PWID people who inject drugs
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high-risk group was doubled from 3.6 to 7.2; 6 % if vac-
cine efficacy was halved after treatment (see ‘Methods’);
6 % if fully assortative mixing was assumed; and 3 %
when the high-risk population proportion was doubled
from 0.17 to 0.34.
Quantitatively similar sensitivity results were found for
different initial chronic prevalence, vaccine efficacy and
treatment numbers, provided treatment numbers alone
were insufficient to achieve complete coverage of the
chronically infected population (approximately 20, 45
and 100/1,000 PWID per year for 15 years in settings
with 25, 50 and 75 % initial chronic HCV prevalence
among PWID respectively).
Discussion
Previous models of HCV vaccines have either not con-
sidered concurrent vaccination and treatment [43–45]
or have compared hypothetical vaccines to older gener-
ation therapies [46]. Here, we have explored the possible
benefits of partially effective HCV vaccines alongside
highly effective treatments. Our results suggest that even
a partially effective HCV vaccine has benefits when used
in conjunction with highly effective treatments in set-
tings with medium (50 %) or high (75 %) chronic HCV
prevalence among PWID. In these settings, prevalence
reduction targets can be achieved with fewer treatment
courses when a vaccination programme exists, which is
Fig. 5 Sensitivity of vaccination strategy: comparison of 15-year relative prevalence reduction when vaccinating after treatment (A) versus vaccinating
in the community under different parameter assumptions (B). The setting was with 50 % initial chronic HCV prevalence among PWID, treating 20/1,000
PWID each year, and using a 30, 60 or 90 % efficacious vaccine. HCV hepatitis C virus, PWID people who inject drugs
Fig. 6 Sensitivity of risk allocation: the additional 15-year relative prevalence reduction that was possible by allocating treatments (20/1,000 PWID
each year) most efficiently to risk groups and vaccinating after treatment in different parameter scenarios. The setting was with 50 % initial chronic HCV
prevalence among PWID and a 60 % efficacious vaccine. HCV hepatitis C virus, PWID people who inject drugs
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likely to save on costs. For example, we estimated that in
Melbourne, Australia, a 50 % relative prevalence reduc-
tion could be achieved with approximately 100 fewer
treatment courses per year if a 60 % efficacious vaccine
were administered after successful treatment. With treat-
ment costs in developed countries (including Australia)
still either in negotiation or unclear, and in some cases
(e.g. the USA) up to US$80,000 a course, combining vac-
cination with treatment is likely to be a cheaper way to
achieve prevalence reduction targets in settings with
medium or high chronic HCV prevalence among PWID
than treatment alone. In Melbourne, this could occur as
long as treatment remains more than five times as ex-
pensive as a potential vaccine (Table 2). With vaccines
for most other diseases costing under US$200 per per-
son [47] this is not unrealistic, even if treatment costs
are substantially reduced.
Administering vaccinations directly after successful
treatment to prevent reinfection would be an efficient
implementation strategy. Vaccinating directly after treat-
ment achieved approximately equal additional preva-
lence reduction as vaccinating similar numbers in the
PWID community, and, further, administering after
treatment would be relatively simple because the person
is already engaged in care with their HCV RNA status
known. This would make simple implementation effect-
ive: in the previous example, treating 26/1,000 PWID
per year would have equivalent effects to treating 22/
1,000 PWID per year if vaccinating after treatment.
Background chronic prevalence was a more important
determinant of a vaccine’s benefit than vaccine efficacy.
In terms of reducing required treatment numbers, a vac-
cine with 30 % efficacy provided greater or equal bene-
fits in a setting with high chronic HCV prevalence
among PWID than a vaccine with 90 % efficacy in set-
tings with low or medium chronic HCV prevalence
among PWID. In many high-prevalence scenarios, a
single vaccination provided almost the same benefit as a
single treatment course. In these cases vaccinating after
treatment would mean that treatment numbers could
almost be halved with minimal effect on prevalence
reduction.
The model had two main sensitivities. First, as the
average length of injecting career increased so did the
impact of treatments and vaccinations on prevalence re-
duction. This reflects the fact that in countries where
longer injecting careers are typical, there is more time to
accrue benefits through these interventions [9]. This is
in contrast to harm reduction interventions (such as
OST and NSPs), where modelling has shown reduced
impact in settings with longer injecting careers owing to
the long duration of coverage required to protect from
infection [48]. Second, as the duration at high risk, and
hence the heterogeneity of the population, increased,
(1) the impact of treatments and vaccinations greatly
increased, (2) vaccinating after treatment became an
increasingly better strategy than community-based
vaccination, and (3) the benefit of allocating treatments
and vaccinations to specific injecting risk groups in-
creased. The latter two changes were related: as the het-
erogeneity increased, the high-risk population in the
model became more likely to be infected than the low-
risk population and therefore more likely to be treated.
This makes vaccination after treatment an implicitly
more risk-targeted strategy, which in this case has in-
creased benefits.
There is some concern that if people seeking treat-
ment are not high-risk injectors, the benefits of vaccinat-
ing after treatment may be diluted. The model did not
support evidence of this at baseline estimates for hetero-
geneity, because even the most efficient allocation of
treatments and vaccinations across risk groups provided
only small additional impact. However, because the ben-
efits of risk-targeted treatment and vaccination strategies
were sensitive to changes in duration at high risk,
situation-specific data should be considered when form-
ing HCV prevalence reduction strategies. For example,
we found that in some settings, in the extreme case
where the average time at high risk was the length of
injecting career, up to 19 % additional relative prevalence
reduction would be forgone if treatments were concen-
trated among low-risk compared to high-risk groups.
Limitations and further work
These estimates are based on a theoretical model and
there is uncertainty in the model parameters. Most im-
portantly, we model a hypothetical vaccine of varying
efficacy with perfect protection for the entire injecting
career. This would require more than 14 years’ coverage,
which is consistent with immunology researchers’ goals.
Additionally, although most parameters come from ob-
servational studies, they are not specific to one location
and may not be relevant to all PWID populations. How-
ever, we have explored a range of prevalence settings
that we hope characterize the range of epidemics found.
The model has assumed no differences between HCV
genotypes when vaccinating or treating PWID, because
immunology researchers are also aiming for cross-
reactive immunity. Implementing combinations of treat-
ment and vaccination numbers simultaneously without
any scale-up period may be unrealistic; however, with a
vaccine not yet developed and treatment currently avail-
able to the public, the approaches governments will take
remain unclear.
This study only considers how the benefits of a vaccine
vary by chronic HCV prevalence among PWID and
under various treatment paradigms, and assumes that
HCV is endemic before treatments and/or vaccinations
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are introduced. Further work should consider the history
of HCV in particular locations and estimate these
relationships using models that are calibrated to the cor-
responding epidemic curves. This would also allow esti-
mation of how the transmission parameter π and R0
have changed over time as a result of changes to risk be-
haviour, and would improve estimation of the threshold
number of susceptible PWID that would need to be vac-
cinated to reduce R0 to below one and lead to eventual
elimination.
Conclusion
Initial HCV prevalence has more impact on the overall
effectiveness of a vaccine than vaccine efficacy. In a set-
ting with high chronic HCV prevalence among PWID,
even modest simultaneous coverage with a low-efficacy
vaccine could significantly reduce the number of treat-
ments required to achieve prevalence reduction targets.
Administering vaccinations directly after successful
treatment would be as effective as and more practical
than vaccinating equal numbers of PWID in the com-
munity, and only minimal benefits could be gained by al-
locating treatments or vaccinations to specific injecting
risk groups. Our results suggest that an HCV vaccine,
even if only modestly efficacious, will play a key role in
HCV elimination over the next 15–20 years.
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